SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amid community debate about its technology and future prospects, with some users expressing skepticism about eVTOL capabilities and range limitations. Bullish investors are pointing to upcoming events like the California International Air Show and potential military contracts as catalysts for growth. A possible collaboration with Tesla has also surfaced as a point of discussion among investors.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The crypto, CAW, is trending due to community enthusiasm around its meme-based identity, "crow with knife," and its expansion across multiple chains. Community members highlight its strong community and deflationary aspects, with many urging others to add it to their watchlist. Bullish sentiment and repetitive "caw caw" messaging dominate the conversation.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network ($REACT) is trending amid community excitement around its cross-chain automation capabilities and the upcoming sunsetting of $PRQ, which some believe has been suppressing its price. The community is also anticipating new exchange listings and marketing campaigns, while highlighting its strong technology and staking rewards. Discussions include potential price targets and the belief that $REACT is an undervalued gem with significant long-term potential.

Roundhill ETF Trust - Roundhill WeeklyPay Universe ETF

Roundhill WeeklyPay™ Universe ETF

The Roundhill WeeklyPay™ Universe ETF ($WPAY) is trending as investors discuss its weekly dividend payouts and compare it to other high-yield ETFs. Community members are actively sharing dividend amounts and payout schedules, while also debating its valuation and potential for NAV erosion. Some are rotating into $WPAY from other dividend plays, drawn to its promise of consistent income.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Glaukos ($GKOS) is trending due to positive Phase 3 trial results for its iDose TR glaucoma treatment, which met primary efficacy endpoints and showed a favorable safety profile. The community is actively discussing the potential for this innovative drug delivery system to disrupt the glaucoma treatment market. Analysts are updating ratings and price targets, reflecting optimism about Glaukos's pipeline and market position in ophthalmic therapies.

Investment Managers Series Trust II - Tradr 2X Long UPST Daily ETF

Tradr 2X Long UPST Daily ETF

Traders are actively discussing $UPSX, a 2x leveraged ETF for Upstart, with many highlighting it as a way to amplify potential gains from $UPST, especially amid anticipation of future rate cuts. The community is weighing the risks and rewards of using the ETF, with some expressing concerns about its correlation to the underlying stock and others seeing it as a potential high-reward play. Overall sentiment leans bullish, with some expecting a significant move if $UPST rebounds.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

HSY is trending amid reports of a potential takeover by Mondelez, driving speculation and a notable price surge. While some traders are betting on a continued rise, others anticipate a pullback if the deal doesn't materialize, given concerns about high cocoa prices and potential market overvaluation.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending due to a mix of factors, including unusual options activity and analyst ratings adjustments. Community discussions include call options activity, potential share buybacks, and its performance relative to peers in the financial sector. Some traders are noting technical indicators and potential entry points, while others discuss the broader market context.

Tenable Holdings, Inc. engages in the development of security software solutions. It offers Cyber Exposure which is a discipline for managing and measuring cybersecurity risk in the digital era. Its products include tenable.io, tenable.sc, tenable.ot, and nessus professional. The firm delivers solutions in the field of application security, cloud security, compliance, energy, finance, healthcare, and retail. The company was founded by John C. Huffard, Jr. and Renaud M. Deraison in 2002 and is headquartered in Columbia, MD.

Tenable Holdings Inc

Tenable Holdings is trending amid discussions of its potential as an AI protection acquisition target and overall cybersecurity sector dynamics. Community members are weighing the company's merits against competitors, with some expressing disappointment in its muted market response despite positive earnings, while others suggest it's a hidden gem. Additionally, recent analyst rating adjustments and price target updates are contributing to the ongoing conversation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Propanc Biopharma tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume, aligning with the volatile trend the stock has been witnessing since the cancer drug developer completed its move from the OTC Pink market to the Nasdaq Capital Market and announced a $4 million share sale.Propanc tumbled nearly 20% in premarket trading Tuesday, after more than doubling on Monday in its best session in four months with a 103.8% gain to $5.85.The company said on Aug. 14 it had secured approval to uplist, with trading on Nasdaq starting Aug. 15 under the same “PPCB” ticker. Its shares were last quoted on the OTC Pink at the close of business Aug. 14.On Thursday, Propanc priced the one million shares at $4 each, targeting $4 million in gross proceeds before costs, and gave underwriters a 45-day option to buy another 150,000 shares.&nbsp;The deal is expected to close on Aug. 18, led by D. Boral Capital and Craft Capital Management.&nbsp;A registration statement for the offering was declared effective by the SEC on Aug. 13.The Melbourne-based biotech said it plans to use the cash for working capital and general expenses.&nbsp;Propanc is developing a proenzyme therapy designed to block the spread and recurrence of solid tumors such as pancreatic, ovarian and colorectal cancers by attacking cancer stem cells.On Stocktwits, retail sentiment for Propanc was ‘extremely bullish’ amid ‘extremely high’ message volume, making it one of the most trending equities on the platform.&nbsp;One user noted that Propanc was looking strong with volume picking up and the chart setting up for what could be the start of a big run.&nbsp;<stembedurl>https://stocktwits.com/Elena11898/message/625706251</stembedurl>Another user remarked that it was lucky no funds chased the stock that day, adding that a drop under $2 might come tomorrow.<stembedurl>https://stocktwits.com/letuan7/message/625718778</stembedurl><a href="https://stocktwits.com/symbol/PPCB">Propanc’s stock</a> has declined 51.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Propanc Biopharma (PPCB) tumbled 17% in after-hours trading on Monday, with activity surging to nearly 33,000 times its usual volume. (Photo credit: Getty Images)

Why Propanc stock Is Tumbling In Premarket Today

The biotech firm announced a $4 million share sale alongside its Nasdaq uplisting, sending trading volumes surging to record levels. 

Equity

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

Propanc Biopharma Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$1.77
Prev Close	$1.84
Open	$1.82
Dividend Yield	0.00%
50-Day Moving Average	$4.14
Beta	0.00
Avg. Volume	414,909.14
PE Ratio	-0.02

52-Week High	$145.46
52-Week Low	$1.25
Market Capitalization	$22.67M
EPS (Annual)	-$14.85
Price to Book	1.48
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

PPCB
Propanc Biopharma Inc

Feed

News

Sentiment

Fundamentals

Info

Latest PPCB News

PPCB Propanc Biopharma Inc